MCID: SWT003
MIFTS: 34

Sweat Gland Disease

Categories: Endocrine diseases, Skin diseases

Aliases & Classifications for Sweat Gland Disease

MalaCards integrated aliases for Sweat Gland Disease:

Name: Sweat Gland Disease 12 15
Sweat Gland Diseases 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1383
ICD10 33 L74 L74.9
ICD9CM 35 705 705.9
MeSH 44 D013543
SNOMED-CT 68 88232005
UMLS 73 C0038986

Summaries for Sweat Gland Disease

MalaCards based summary : Sweat Gland Disease, also known as sweat gland diseases, is related to inverted transitional papilloma and balloon cell malignant melanoma, and has symptoms including pruritus, increased sweating and exanthema. An important gene associated with Sweat Gland Disease is NTRK1 (Neurotrophic Receptor Tyrosine Kinase 1), and among its related pathways/superpathways are Neuroscience and Keratinization. The drugs Oxybutynin and Terazosin have been mentioned in the context of this disorder. Affiliated tissues include skin, ovary and pituitary, and related phenotype is integument.

Wikipedia : 76 Sweat glands, also known as sudoriferous or sudoriparous glands, from Latin sudor, meaning ''sweat'',... more...

Related Diseases for Sweat Gland Disease

Diseases related to Sweat Gland Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 100)
# Related Disease Score Top Affiliating Genes
1 inverted transitional papilloma 10.3 KRT5 KRT7
2 balloon cell malignant melanoma 10.3 KRT5 KRT7
3 ceruminoma 10.3 KRT5 KRT7
4 lichen planopilaris 10.3 KRT14 KRT5
5 epidermolysis bullosa simplex, autosomal recessive 1 10.3 KRT14 KRT5
6 malignant spiradenoma 10.3 KRT5 KRT7
7 benign mesothelioma 10.3 KRT5 KRT7
8 sensory organ benign neoplasm 10.3 KRT5 KRT7
9 bile duct mucoepidermoid carcinoma 10.3 KRT5 KRT7
10 middle ear adenoma 10.3 KRT5 KRT7
11 epidermolysis bullosa simplex, localized 10.3 KRT14 KRT5
12 epidermolysis bullosa simplex, generalized 10.3 KRT14 KRT5
13 pediatric fibrosarcoma 10.3 EWSR1 NTRK1
14 vulvar sarcoma 10.3 EWSR1 KRT7
15 breast squamous cell carcinoma 10.2 KRT14 KRT5
16 epidermolysis bullosa simplex with mottled pigmentation 10.2 KRT14 KRT5
17 anus basaloid carcinoma 10.2 CYLD KRT7
18 prolactin producing pituitary tumor 10.2 NGF NTRK1
19 malignant biphasic mesothelioma 10.2 KRT5 KRT7
20 odontoma 10.2 KRT14 KRT5
21 hidrocystoma 10.2 KRT15 KRT7
22 prostate squamous cell carcinoma 10.2 KRT5 KRT7
23 benign breast adenomyoepithelioma 10.2 KRT14 KRT5 KRT7
24 conjunctival nevus 10.2 NGF NTRK1
25 breast adenomyoepithelioma 10.2 KRT14 KRT5 KRT7
26 large cell acanthoma 10.2 KRT14 KRT5 KRT7
27 chronic cystitis 10.2 KRT7 NGF
28 breast myoepithelial neoplasm 10.2 KRT14 KRT5 KRT7
29 peritoneum cancer 10.2 KRT5 KRT7
30 anal canal squamous cell carcinoma 10.2 KRT5 NCSTN
31 lipoadenoma 10.2 KRT14 KRT5 KRT7
32 pregnancy adenoma 10.2 KRT14 KRT5 KRT7
33 intraneural perineurioma 10.2 KRT14 KRT5 KRT7
34 oropharynx cancer 10.2 KRT14 KRT5 KRT7
35 gastric squamous cell carcinoma 10.2 KRT5 KRT7
36 primary cutaneous amyloidosis 10.2 KRT14 KRT5 KRT7
37 vesiculobullous skin disease 10.2 KRT14 KRT5
38 papilloma 10.2 KRT14 KRT5 KRT7
39 dowling-degos disease 10.2 KRT14 KRT5 NCSTN
40 lymphoepithelioma-like carcinoma 10.2 KRT5 KRT7
41 insensitivity to pain, congenital, with anhidrosis 10.2 NAA50 NTRK1
42 seminal vesicle adenocarcinoma 10.2 EDA KRT7
43 askin's tumor 10.2 EWSR1 NGF NTRK1
44 spiradenoma 10.2 CYLD KRT14 KRT7
45 brooke-spiegler syndrome 10.2 CYLD KRT14 KRT7
46 eccrine papillary adenocarcinoma 10.1 KRT7 PGR
47 predominantly cortical thymoma 10.1 KRT14 PGR
48 cystadenofibroma 10.1 KRT5 KRT7
49 anhidrosis 10.1 GLA NGF NTRK1
50 endosalpingiosis 10.1 KRT7 PGR

Graphical network of the top 20 diseases related to Sweat Gland Disease:



Diseases related to Sweat Gland Disease

Symptoms & Phenotypes for Sweat Gland Disease

UMLS symptoms related to Sweat Gland Disease:


pruritus, increased sweating, exanthema

MGI Mouse Phenotypes related to Sweat Gland Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.17 CYLD KRT14 KRT5 NCSTN NGF NTRK1

Drugs & Therapeutics for Sweat Gland Disease

Drugs for Sweat Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 110)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxybutynin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 5633-20-5 4634
2
Terazosin Approved Phase 4,Not Applicable 63590-64-7 5401
3
Prazosin Approved Phase 4,Not Applicable 19216-56-9 4893
4
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
5
Adalimumab Approved Phase 4,Phase 3,Phase 2 331731-18-1 16219006
6 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
8 Anti-Infective Agents, Urinary Phase 4,Phase 3,Phase 2,Not Applicable
9 Renal Agents Phase 4,Phase 3,Phase 2,Not Applicable
10 Muscarinic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Parasympatholytics Phase 4,Phase 3,Phase 2,Not Applicable
15 Mandelic Acids Phase 4,Phase 3,Phase 2,Not Applicable
16 Cholinergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Adrenergic alpha-1 Receptor Antagonists Phase 4,Not Applicable
18 Psychotropic Drugs Phase 4,Phase 1,Not Applicable
19 Adrenergic Antagonists Phase 4,Not Applicable
20 Adrenergic Agents Phase 4,Phase 2,Not Applicable
21 Antihypertensive Agents Phase 4,Not Applicable
22 Antidepressive Agents Phase 4,Phase 1,Not Applicable
23 Adrenergic alpha-Antagonists Phase 4,Not Applicable
24 Botulinum Toxins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 onabotulinumtoxinA Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Botulinum Toxins, Type A Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 abobotulinumtoxinA Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Acetylcholine Release Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Neuromuscular Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
32 Anesthetics Phase 4,Phase 2,Phase 1,Not Applicable
33
Aluminum chloride Approved Phase 3,Phase 1,Not Applicable 7446-70-0
34 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
35 Anti-Bacterial Agents Phase 3,Phase 2,Not Applicable
36 Antibiotics, Antitubercular Phase 3,Not Applicable
37 Bromides Phase 3,Phase 2,Phase 1
38 Anticonvulsants Phase 3,Phase 1
39 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1,Early Phase 1
40 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Immunoglobulins Phase 3,Phase 2,Phase 1,Early Phase 1
42 Antibodies Phase 3,Phase 2,Phase 1,Early Phase 1
43 Astringents Phase 3,Phase 1
44
Apremilast Approved, Investigational Phase 2 608141-41-9 11561674
45
Ustekinumab Approved, Investigational Phase 2 815610-63-0
46
Infliximab Approved Phase 2 170277-31-3
47
Etanercept Approved, Investigational Phase 2 185243-69-0
48
Liraglutide Approved Phase 2 204656-20-2 44147092
49
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
50
Nivolumab Approved Phase 2 946414-94-4

Interventional clinical trials:

(show top 50) (show all 152)
# Name Status NCT ID Phase Drugs
1 Hyperhydrosis Treatment Using Botulinum Toxin Completed NCT03816046 Phase 4 botulinum toxin A
2 Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control Study Completed NCT01310712 Phase 4 Oxybutynin;placebo
3 VASER Treatment of Axillary Hyperhidrosis/Bromidrosis Completed NCT00735293 Phase 4
4 Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin Completed NCT00449683 Phase 4 terazosin
5 A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis Completed NCT00168480 Phase 4
6 A Study Using Botulinum Toxin Type A in Adolescents With Axillary Hyperhidrosis Completed NCT00168415 Phase 4
7 Safety and Efficacy of Humira (Adalimumab) for Hidradenitis Suppurativa (HS) Peri-Surgically (SHARPS Study) Recruiting NCT02808975 Phase 4 Adalimumab;Placebo
8 Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS Not yet recruiting NCT03221621 Phase 4 Adalimumab Injection
9 Unicentric Comparing Study of Suction Curettage With Standard BOTOX Injection in the Treatment of Patients With Essential Axillar Hyperhidrosis: Comparing of Efficacy, Duration of Effectiveness, and Adverse Events. Terminated NCT00669474 Phase 4 Treatment with Botox
10 GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis Completed NCT01128738 Phase 3 GSK1358820;Placebo
11 Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis Completed NCT02553798 Phase 3 Glycopyrronium Topical Wipes
12 Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis Completed NCT02530294 Phase 3 glycopyrronium Topical Wipes
13 Study of Glycopyrronium in Axillary Hyperhydrosis Completed NCT02530281 Phase 3 glycopyrronium Topical Wipes
14 Treatment of Hyperhidrosis With Oxybutynin Completed NCT01855256 Phase 3 Oxybutynin;Placebo
15 Liposuction as Treatment for Excessive Axillary Sweat Completed NCT00228072 Phase 2, Phase 3
16 A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis Completed NCT00168402 Phase 3 Botulinum Toxin Type A
17 Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa Completed NCT01635764 Phase 3
18 Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa Completed NCT01468233 Phase 3
19 Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa Completed NCT01468207 Phase 3
20 The Use of Human Acellular Dermal Matrix to Improve Infraauricular Depressed Deformities and Frey's Syndrome Completed NCT01414790 Phase 3
21 Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary Hyperhidrosis Recruiting NCT03760198 Phase 3 Meditoxin
22 Assessment of Efficacy and Safety of Topical Administration of 1% Glycopyrronium Bromide (GPB) in Patients With Primary Axillary Hyperhidrosis and the Assessment of Long-term Efficacy and Safety of Topical Administration of 1% GPB Cream in Patients With Primary Axillary Hyperhidrosis. Recruiting NCT03658616 Phase 3 WO3970;Placebo (WO3988)
23 A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis Recruiting NCT03627468 Phase 3 Sofpironium Bromide Gel, 5%;Sofpironium Bromide Gel, 15%
24 Topical Aluminium Chloride vs OnabotulinumtoxinA Intradermal Injections in Residual Limb Hyperhidrosis (Lower Limbs) Recruiting NCT03433859 Phase 3 OnabotulinumtoxinA
25 Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa Recruiting NCT02805595 Phase 3 23.4% Hypertonic saline;Saline
26 Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa Active, not recruiting NCT02904902 Phase 3 Adalimumab
27 Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) Not yet recruiting NCT03713632 Phase 3 Secukinumab;Placebo
28 This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). Not yet recruiting NCT03713619 Phase 3 secukinumab;placebo
29 BTX-A Treatment for Palmar Hyperhidrosis Terminated NCT01262339 Phase 2, Phase 3 BTX-A
30 To Determine the Efficacy of a Laser Device for the Treatment of Hidradenitis Suppurativa Terminated NCT00367328 Phase 3
31 Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary Hyperhidrosis Withdrawn NCT02099695 Phase 3 Oxybutynin;Placebo
32 A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis Completed NCT03024255 Phase 2 BBI-4000 Concentration 1;BBI-4000 Concentration 2;BBI-4000 Concentration 3;Vehicle (Placebo)
33 A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar Hyperhidrosis Completed NCT02682238 Phase 2 BBI-4000, 15%
34 A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects Completed NCT02673619 Phase 2 Umeclidinium;Vehicle
35 Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis Completed NCT02565732 Phase 2
36 Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis Completed NCT02563899 Phase 2 Umeclidinium;Vehicle
37 Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis Completed NCT02479139 Phase 2
38 A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis Completed NCT02336503 Phase 2 BBI-4000 Low Concentration;BBI-4000 Middle Concentration;BBI-4000 High Concentration;Placebo
39 Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis Completed NCT02193139 Phase 2 WL8713, 6 mg;WL8713, 12 mg;WL8713, 18 mg;WL8713, 24 mg;Placebo
40 Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis Completed NCT02129660 Phase 2 Dose 1 of glycopyrrolate, 2.0% QD;Dose 2 of glycopyrrolate, 3.0% QD;Dose 1 of glycopyrronium, 2.5% QD;Dose 2 of glycopyrronium, 3.75% QD
41 A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis Completed NCT02016885 Phase 2 glycopyrrolate, 1.0%;glycopyrrolate, 2.0%;glycopyrrolate, 3.0%;glycopyrrolate, 4.0%
42 Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis Completed NCT01799824 Phase 2
43 A Study to Compare Oxybutynin to a Placebo in Women and the Effect on Plantar Hyperhidrosis Completed NCT01328015 Phase 2 Oxybutynin 5 mg pills
44 Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis Completed NCT03049267 Phase 2 Apremilast;Placebo Oral Tablet
45 Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT03001622 Phase 2
46 Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa Completed NCT02695212 Phase 2 Apremilast
47 MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB Completed NCT02643654 Phase 2 MABp1;Placebo
48 Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients Completed NCT02421172 Phase 2
49 A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa Completed NCT01704534 Phase 2 Ustekinumab
50 Anakinra in Hidradenitis Suppurativa Completed NCT01558375 Phase 2 Water for injection;Anakinra

Search NIH Clinical Center for Sweat Gland Disease

Cochrane evidence based reviews: sweat gland diseases

Genetic Tests for Sweat Gland Disease

Anatomical Context for Sweat Gland Disease

MalaCards organs/tissues related to Sweat Gland Disease:

41
Skin, Ovary, Pituitary, Tonsil, Prostate

Publications for Sweat Gland Disease

Variations for Sweat Gland Disease

Expression for Sweat Gland Disease

Search GEO for disease gene expression data for Sweat Gland Disease.

Pathways for Sweat Gland Disease

Pathways related to Sweat Gland Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.16 GFAP NCSTN NGF NTRK1
2
Show member pathways
11.91 KRT14 KRT15 KRT5 KRT7
3
Show member pathways
11.47 GFAP NCSTN PGR
4
Show member pathways
10.96 GFAP KRT14 KRT5 KRT7
5
Show member pathways
10 NGF NTRK1

GO Terms for Sweat Gland Disease

Cellular components related to Sweat Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratin filament GO:0045095 9.13 KRT14 KRT5 KRT7
2 intermediate filament GO:0005882 9.02 GFAP KRT14 KRT15 KRT5 KRT7

Biological processes related to Sweat Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 epidermis development GO:0008544 9.5 KRT14 KRT15 KRT5
2 neurotrophin TRK receptor signaling pathway GO:0048011 9.4 NGF NTRK1
3 positive regulation of Ras protein signal transduction GO:0046579 9.37 NGF NTRK1
4 hemidesmosome assembly GO:0031581 9.26 KRT14 KRT5
5 keratinization GO:0031424 9.26 KRT14 KRT15 KRT5 KRT7
6 nerve growth factor signaling pathway GO:0038180 9.16 NGF NTRK1
7 cornification GO:0070268 8.92 KRT14 KRT15 KRT5 KRT7

Molecular functions related to Sweat Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.83 CYLD EDA EWSR1 GFAP GLA KRT14
2 structural constituent of cytoskeleton GO:0005200 8.92 GFAP KRT14 KRT15 KRT5

Sources for Sweat Gland Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....